Unlocking the Potential of ABHD15: A Potential Drug Target and Biomarker

Target Name: ABHD15

NCBI ID: G116236

ABHD15

Unlocking the Potential of ABHD15: A Potential Drug Target and Biomarker

Alpha/beta hydrolase domain-containing protein 15 (ABHD15) is a protein that has been identified as a potential drug target and biomarker. ABHD15 is a member of the superfamily of alpha/beta hydrolases, which are a group of enzymes involved in the hydrolysis of a wide range of intracellular and extracellular peptides and proteins. The alpha/beta hydrolases are classified into three subfamilies, including ABHD11 (alpha/beta-lactamases), ABHD12 (alpha/beta-glucosidases), and ABHD15 (alpha/beta-hydrolases).

The Discovery of ABHD15

ABHD15 was first identified as a gene encoding a protein with homology to the alpha/beta hydrolases. The protein sequence analysis revealed that ABHD15 had a distinct alpha/beta hydrolase domain, which is characterized by a catalytic core composed of a parallel beta sheet and a catalytic loop. The alpha/beta sheet contained several conserved acidic and basic residues that are involved in the formation of a hydrophobic environment around the catalytic loop.

The Expression and Localization of ABHD15

ABHD15 is expressed in various tissues and cells of the human body, including the liver, pancreas, and gut. The protein is predominantly localized to the endoplasmic reticulum (ER) and to the cytoplasm. There is some evidence to suggest that ABHD15 may be involved in the regulation of cellular processes, including cell signaling, apoptosis, and inflammation.

The Potential Therapeutic Benefits of ABHD15

The discovery of ABHD15 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. One of the potential therapeutic benefits of ABHD15 is its involvement in the regulation of cellular processes that are affected by numerous diseases, including diabetes, cancer, and neurodegenerative diseases.

For example, ABHD15 has been shown to be involved in the regulation of insulin secretion and sensitivity. Insulin is a critical hormone that regulates blood sugar levels, and its levels are often affected by various diseases, including diabetes. ABHD15 has been shown to play a role in the regulation of insulin sensitivity by modulating the activity of several intracellular signaling pathways, including the TGF-beta pathway and the PI3K/Akt pathway.

In addition, ABHD15 has also been shown to be involved in the regulation of cell signaling pathways that are involved in cancer development. For instance, ABHD15 has been shown to be involved in the regulation of the androgen signaling pathway, which is involved in the development and progression of many types of cancer.

Another potential therapeutic benefit of ABHD15 is its involvement in the regulation of neurodegenerative diseases. ABHD15 has been shown to play a role in the regulation of the neurotransmitter serotonin, which is involved in the regulation of mood, appetite, and sleep. In addition, ABHD15 has been shown to be involved in the regulation of the pain signaling pathway, which is involved in the development and treatment of chronic pain.

The Potential for ABHD15 as a Drug Target

The potential drug targeting of ABHD15 is based on its unique structure and its involvement in several cellular processes that are affected by numerous diseases. One of the potential strategies for targeting ABHD15 is the use of small molecules, such as drugs that can modulate its activity.

In addition, ABHD15 may also be a useful biomarker for the diagnosis and monitoring of various diseases. For example, the levels of ABHD15 have been shown to be affected by a wide range of diseases

Protein Name: Abhydrolase Domain Containing 15

The "ABHD15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets